Continuum Advisory’s BioNTech BNTX Stock Holding History

Continuum Advisory’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-32	Closed	-$3.65K	–	1701
2024 Q4	$3.65K	Buy	32 +22	+220%	+$2.51K	﹤0.01%	1217
2024 Q3	$1.04K	Buy	+10	New	+$919	﹤0.01%	1613

Other funds holding BNTX

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $21.4B AUM 8.31% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Continuum Advisory's BNTX Position: Q1 2025 in Review

Continuum Advisory sold out of BioNTech (BNTX) in Q1 2025, closing a stake of 32 shares — an estimated $3.65K sold.

Continuum Advisory first reported a position in BNTX in Q3 2024 and held it in 2 quarters. The position peaked at $3.65K in Q4 2024. 280 funds tracked by Wall St. Rank hold BNTX as of Q1 2025.

Continuum Advisory reported no remaining BioNTech position as of Q1 2025 after selling out during the quarter.
Continuum Advisory sold 32 BioNTech shares in Q1 2025, an estimated $3.65K.
Continuum Advisory first reported a position in BioNTech in Q3 2024 and held it in 2 quarters.
Continuum Advisory's BioNTech position peaked at $3.65K in Q4 2024.
280 funds tracked by Wall St. Rank held BioNTech as of Q1 2025.

Based on Continuum Advisory's 13F filing for Q1 2025, filed 23 Apr 2025.